Opinion

Video

Ethical Implications of Patient Access Restrictions

Jessica Nance, MD, MS, and Emma Ciafaloni, MD, FAAN, discuss ethical dilemmas, exploring how patient subgroup restrictions on orphan drugs can impact access and cost control.

This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA; Jessica Nance, MD, MS; Kimberly C. Chen, DO, MSHLM; Emma Ciafaloni, MD, FAAN; and Mary Pak, MD, FACP.

Haumschild engages in a discussion with Nance and Ciafaloni regarding the ethical challenges posed by patient subgroup restrictions on orphan drugs. Nance highlights the difficulties providers face when forced to deny treatment based on rigid approval criteria, emphasizing the need for flexible communication channels with decision makers. Ciafaloni emphasizes the societal responsibility to ensure equitable access to revolutionary therapies like gene therapy, urging collaborative efforts among stakeholders. The dialogue underscores the importance of open communication, involving key opinion leaders, providers, and patient advocacy groups to strike a balance between cost control and patient access. As they navigate these ethical dilemmas, the consensus emerges that prioritizing collaboration over financial considerations is paramount in ensuring fair and equitable access to life-altering treatments.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
1 expert in this video
1 expert in this video
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
1 expert in this video
1 expert in this video
1 KOL is featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo